Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Hydroxychloroquine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Neoplasm, Residual 1 Melanoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Fulvestrant 32 Letrozole 27 Paclitaxel 22 ribociclib 20 Trastuzumab 20 Specimen Handling 19 Tamoxifen 18 Anastrozole 17 pembrolizumab 16 palbociclib 16 exemestane 16 Carboplatin 16 Capecitabine 16 abemaciclib 13 Cyclophosphamide 12 pertuzumab 11 trastuzumab deruxtecan 10 Magnetic Resonance Spectroscopy 10 Biopsy 10 Surveys and Questionnaires 9 olaparib 8 Blood Specimen Collection 8 Taxes 7 Radiation 7 130-nm albumin-bound paclitaxel 7 inavolisib 6 eribulin 6 elacestrant 6 Mastectomy, Segmental 6 Gemcitabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2026-04-09

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡